The cost and inefficiency of the drug
development process can be eased with the help of organ-on-chip and 3D cell culture technology. A wide range of technology in this arena has been
developed; however, what comprises an 'ideal' 3D culture model has not
been defined and translation has proven difficult.
A new article published in Future Science OA from Shery Huang and colleagues at the University of Cambridge (UK) has attempted to address this issue by determining the ideal qualities of such technology from the point of view of the end users, the biomedical community.
"Although a plethora of microfluidics-based culture models has been developed, the adaptation of these models to address biologically focused research questions is sparse," noted the authors.
"In order to become a widely accepted tool in fundamental bioscience and pharmaceutical industry, 3D culture models have to find suitable research questions to address and impart tailored complexity, while overcoming drawbacks such as poor compatibility, relatively low throughput, limited functionality and lack of a standardized metric in cross-system comparison," concluded the authors.
They hope that the survey results can provide insight for entrepreneurs interested in the commercialization of these systems.